Literature DB >> 9090749

Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis.

K Akiyama1, K Shikata, H Sugimoto, M Matsuda, Y Shikata, N Fujimoto, K Obata, H Matsui, H Makino.   

Abstract

One of the major causes of glomerular sclerosis which precedes renal failure is an increase in glomerular extracellular matrices (ECMs). Glomerular ECMs which are composed of mesangial matrix and basement membrane play an important role in physical, mechanical and structural functions of the glomerulus. Matrix metalloproteinases (MMPs) are the enzymes which degrade both the collagenous and noncollagenous components of the ECMs. Tissue inhibitors of metalloproteinases (TIMPs) are inhibitors of MMPs. The regulations by MMPs and TIMPs are considered to contribute to maintain homeostasis in the production and degradation of ECMs in the glomeruli. In the glomeruli of patients with glomerulonephritis, the imbalance between production and degradation of ECMs is supposed to cause the increase in ECMs and glomerular sclerosis. In this study, serum concentrations of MMP-1, -2, and -3, TIMP-1 and 2 and type IV collagen were measured in patients with IgA nephropathy, lupus nephritis and membranous nephropathy. In patients with IgA nephropathy and lupus nephritis which are mesangial proliferative glomerulonephritis, the levels of MMP-3 and TIMP-2 were increased. On the other hand, the levels of type IV collagen, MMP-2 and TIMP-1 were increased in patients with membranous nephropathy in which the thickening of basement membrane is characteristic. These differences may be caused by the difference of the pathogenesis of these diseases. The present results suggest that the imbalance between the metabolism of ECMs occurs in patients with glomerulonephritis and contributes to the progression of glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090749

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  10 in total

1.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining.

Authors:  Tetsuya Endo; Kimimasa Nakabayashi; Makiho Sekiuchi; Tadahide Kuroda; Akinori Soejima; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

3.  Urinary Markers of Podocyte Dysfunction in Chronic Glomerulonephritis.

Authors:  Natalia Chebotareva; Irina Bobkova; Lidia Lysenko; Sergey Moiseev
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus.

Authors:  A Faber-Elmann; Z Sthoeger; A Tcherniack; M Dayan; E Mozes
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

5.  Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis.

Authors:  Zhongxin Jiang; Tao Sui; Bin Wang
Journal:  Rheumatol Int       Date:  2009-09-25       Impact factor: 2.631

6.  Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy.

Authors:  Kyoichi Tashiro; Ichiro Koyanagi; Ikko Ohara; Takamichi Ito; Akemi Saitoh; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

7.  Proteolytic cleavage of type I collagen generates an autoantigen in autoimmune uveitis.

Authors:  Purushottam Jha; Balasubramanian Manickam; Bharati Matta; Puran S Bora; Nalini S Bora
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

8.  Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

9.  Association between Serum Matrix Metalloproteinase- (MMP-) 3 Levels and Systemic Lupus Erythematosus: A Meta-analysis.

Authors:  Jiwon M Lee; Andreas Kronbichler; Se Jin Park; Seong Heon Kim; Kyoung Hee Han; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Ki Hwan Kim; Gaeun Kim; Dong Soo Kim; Hyun Wook Chae; Chul Ho Lee; Keum Hwa Lee; Jae Il Shin
Journal:  Dis Markers       Date:  2019-07-18       Impact factor: 3.434

10.  The Metalloproteinase ADAMTS5 Is Expressed by Interstitial Inflammatory Cells in IgA Nephropathy and Is Proteolytically Active on the Kidney Matrix.

Authors:  Scott Taylor; Molly Whitfield; Jonathan Barratt; Athanasios Didangelos
Journal:  J Immunol       Date:  2020-09-11       Impact factor: 5.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.